share_log

BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT

BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT

BIOVAXYS宣佈計劃進行私募融資
PR Newswire ·  03/23 05:05

VANCOUVER, BC, March 22, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") announces that it intends to complete a non-brokered private placement (the "Private Placement") consisting of up to 15,384,615 units ("Units") at a price of $0.065 per Unit for total gross proceeds of up to CAD$1,000,000, before deducting any offering-related expenses. Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant"). Each Warrant is exercisable for one additional Common Share at an exercise price of $0.15 for a period of 24 months.

不列顛哥倫比亞省溫哥華,2024年3月22日 /PRNewswire/ — BioVaxys Technology Corp.(CSE:BIOV)(FRA:5LB)(場外交易代碼:BVAXF)(“BioVaxys” 或 “公司”)宣佈,它打算按價格完成一項不超過15,384,615個單位(“單位”)的非經紀私募配售(“私募配售”)在扣除任何與發行相關的費用之前,每單位0.065美元,總收益最高爲1,000,000加元。每個單位由一股普通股(“普通股”)和一份完整的普通股購買權證(“認股權證”)組成。每份認股權證可額外行使一股普通股,行使價爲0.15美元,爲期24個月。

Closing of the private placement is conditional upon finalizing all contractual documentation and receipt of all applicable regulatory approvals and the policies of the Canadian Securities Exchange ("CSE"). All securities issued pursuant to the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance. The Company intends to use the net proceeds of the Private Placement for general working capital purposes, including, enabling the Company to fund and advance its business plans in regard to its successful recent acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX immune educating platform technology, developed by the former Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA ("IMV") on February 16th, 2024.The Company may pay a finder's fee related to the financing.

私募的完成前提是完成所有合同文件並獲得所有適用的監管批准和加拿大證券交易所(“CSE”)的政策。所有根據私募發行的證券均受自發行之日起四個月零一天的法定持有期限。公司打算將私募的淨收益用於一般營運資金用途,包括使公司能夠爲其最近成功收購腫瘤、傳染病、抗原脫敏和其他免疫學領域的全部發現、臨床前和臨床開發階段資產組合提供資金和推進其業務計劃,這些資產基於加拿大前生物技術公司IMMV Inc.Immunovacc.開發的DPX免疫教育平台技術 Ine Technologies Inc. 和 IMV USA(”IMV”)將於2024年2月16日生效。公司可能會支付與融資相關的發現費。

About BioVaxys Technology Corp.

關於 BioVaxys 科技公司

BioVaxys Technology Corp. (), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and it's HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.

BioVaxys Technology Corp. () 是一家在加拿大不列顛哥倫比亞省註冊的生物製藥公司,是一家臨床階段的生物製藥公司,致力於通過基於DPX免疫教育技術平台及其Haptenix “新抗原” 腫瘤細胞構建平台的新型免疫療法改善患者生活,用於治療癌症、傳染病、抗原脫敏和其他免疫學領域。該公司的臨床階段產品線包括MaveropePimut-S,它正處於晚期復發難治性瀰漫性大B細胞淋巴瘤(DLBCL)和耐鉑性卵巢癌的二期臨床開發,以及使用其專有的Haptenix'新抗原'腫瘤細胞構建平台的個性化免疫治療疫苗,該平台即將在西班牙進入I期,用於治療屈光晚期卵巢癌。BVX-0918該公司還利用其腫瘤免疫學專業知識,利用其個性化免疫治療疫苗創建了獨特的T淋巴細胞和其他數據集庫,以利用預測算法和其他技術來識別新的可靶向腫瘤抗原。BioVaxys的普通股在CSE上市,股票代碼爲 “BIOV”,並在法蘭克福證券交易所(FRA:5LB)和美國(場外交易代碼:BVAXF)上市。欲了解更多信息,請訪問並通過 X 和 LinkedIn 聯繫我們。

ON BEHALF OF THE BOARD

代表董事會

Signed "James Passin"
James Passin, CEO
+1 646 452 7054

簽名 “詹姆斯·帕森”
首席執行官詹姆斯·帕辛先生
+1 646 452 7054

Logo -

徽標-

SOURCE BioVaxys Technology Corp.

來源 bioVaxys 科技公司

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論